the patient. They have focussed on incorporating precursors for hydrogen peroxide and peracetic acid within nanoparticles. This approach is preferred because not only are both agents highly reactive oxidative biocides with disseminated targets, and hence do not give rise to resistance; but both have low systemic toxicity and breakdown to give benign residues.

To date Aga Nanotech has successfully incorporated a range of precursors in two types of PLGA nanoparticles. For one of these routes simple controlled release has been demonstrated. Initial in vitro trials are under way and a collaboration to develop the project further is being explored. Initial in vitro studies have commenced in 2015. The company has filed a patent application.